Answers are grounded in this paper and cite their sources.
This paper reviews the updated indications, physiological effects, and clinical implications of intravenous inotropic agents in the management of refractory heart failure.
Part of the management of refractory heart failure is treatment aimed at preventing organ damage due to inadequate oxygen delivery, improving hemodynamics, and maximizing cardiac output while maintaining only mildly elevated ventricular filling pressures The aim of this paper is to review the most updated indications on intravenous inotropic agents, and to compare their cardiac and peripheral effects. Finally, clinical implications of their use (alone or in combination) are reviewed.
No takes yet. Share an insight, caveat, or question.
Opasich et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: